FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071420516> ?p ?o ?g. }

• W2071420516 endingPage "32" @default.
• W2071420516 startingPage "20" @default.
• W2071420516 abstract "Mutations in the APP gene lead to enhanced cleavage by the beta- and gamma-secretase, and increased Abeta formation, which are tightly associated with Alzheimer's disease (AD)-like neuropathological changes. To examine whether depositions of Abeta by APP mutations are increased, and if this is associated with potential pathogenic phenotypes, the APPsw was expressed in a transgenic line under the control of the neuron-specific enolase (NSE) promoter. A behavioral dysfunction was shown at 12 months, and intensive staining bands, with APP and Abeta-42 antibodies, were visible in the brains of transgenic mice. Of the MAPK family, both JNK and p38 were activated in the brains of transgenic mice, whereas there was no significant activation of the ERK. In parallel, tau phosphorylation was also enhanced in the transgenic relative to the control mice. Moreover, the Cox-2 levels, from Western blot and immunostaining, were increased in the brains of the transgenic line. Furthermore, there were significant caspase-3- and TUNEL-stained nuclei in the transgenic line compared to the age-matched control mice. Thus, these results suggest that NSE-controlled APPsw transgenic mice appear to be a more relevant model in neuropathological phenotypes of AD, and thus could be useful in developing new therapeutic treatments for targeting the aberrant phenotypes that appear in these mice." @default.
• W2071420516 created "2016-06-24" @default.
• W2071420516 creator A5000413124 @default.
• W2071420516 creator A5003767064 @default.
• W2071420516 creator A5004226596 @default.
• W2071420516 creator A5008797659 @default.
• W2071420516 creator A5017205527 @default.
• W2071420516 creator A5032737539 @default.
• W2071420516 creator A5040082997 @default.
• W2071420516 creator A5054640204 @default.
• W2071420516 creator A5058654379 @default.
• W2071420516 creator A5060850021 @default.
• W2071420516 creator A5071751387 @default.
• W2071420516 creator A5090475894 @default.
• W2071420516 date "2004-03-01" @default.
• W2071420516 modified "2023-10-03" @default.
• W2071420516 title "Aberrant expressions of pathogenic phenotype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw" @default.
• W2071420516 cites W1500435375 @default.
• W2071420516 cites W1543551659 @default.
• W2071420516 cites W1558509021 @default.
• W2071420516 cites W1567490604 @default.
• W2071420516 cites W1572812739 @default.
• W2071420516 cites W1605023308 @default.
• W2071420516 cites W1693283493 @default.
• W2071420516 cites W1966103571 @default.
• W2071420516 cites W1973130935 @default.
• W2071420516 cites W1975627206 @default.
• W2071420516 cites W1978566291 @default.
• W2071420516 cites W1978677685 @default.
• W2071420516 cites W1979482832 @default.
• W2071420516 cites W1980225806 @default.
• W2071420516 cites W1980906872 @default.
• W2071420516 cites W1982637771 @default.
• W2071420516 cites W1985964521 @default.
• W2071420516 cites W1987785848 @default.
• W2071420516 cites W1995515835 @default.
• W2071420516 cites W1996664269 @default.
• W2071420516 cites W1999206064 @default.
• W2071420516 cites W2000706612 @default.
• W2071420516 cites W2001210466 @default.
• W2071420516 cites W2001499667 @default.
• W2071420516 cites W2001751920 @default.
• W2071420516 cites W2010778459 @default.
• W2071420516 cites W2017169966 @default.
• W2071420516 cites W2021338058 @default.
• W2071420516 cites W2021675664 @default.
• W2071420516 cites W2023187813 @default.
• W2071420516 cites W2023559337 @default.
• W2071420516 cites W2027895574 @default.
• W2071420516 cites W2029923284 @default.
• W2071420516 cites W2030190314 @default.
• W2071420516 cites W2033165431 @default.
• W2071420516 cites W2037132500 @default.
• W2071420516 cites W2039453997 @default.
• W2071420516 cites W2041214001 @default.
• W2071420516 cites W2046265708 @default.
• W2071420516 cites W2046519538 @default.
• W2071420516 cites W2049167261 @default.
• W2071420516 cites W2053642376 @default.
• W2071420516 cites W2054223500 @default.
• W2071420516 cites W2059696821 @default.
• W2071420516 cites W2063236931 @default.
• W2071420516 cites W2064093411 @default.
• W2071420516 cites W2064470441 @default.
• W2071420516 cites W2064644219 @default.
• W2071420516 cites W2068814836 @default.
• W2071420516 cites W2070045579 @default.
• W2071420516 cites W2081095372 @default.
• W2071420516 cites W2082452384 @default.
• W2071420516 cites W2088151512 @default.
• W2071420516 cites W2092087748 @default.
• W2071420516 cites W2094765619 @default.
• W2071420516 cites W2100610042 @default.
• W2071420516 cites W2100915449 @default.
• W2071420516 cites W2101626807 @default.
• W2071420516 cites W2106083328 @default.
• W2071420516 cites W2116155138 @default.
• W2071420516 cites W2133019124 @default.
• W2071420516 cites W2135841642 @default.
• W2071420516 cites W2146506441 @default.
• W2071420516 cites W93511798 @default.
• W2071420516 doi "https://doi.org/10.1016/j.expneurol.2003.09.021" @default.
• W2071420516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14980807" @default.
• W2071420516 hasPublicationYear "2004" @default.
• W2071420516 type Work @default.
• W2071420516 sameAs 2071420516 @default.
• W2071420516 citedByCount "61" @default.
• W2071420516 countsByYear W20714205162012 @default.
• W2071420516 countsByYear W20714205162013 @default.
• W2071420516 countsByYear W20714205162014 @default.
• W2071420516 countsByYear W20714205162015 @default.
• W2071420516 countsByYear W20714205162016 @default.
• W2071420516 countsByYear W20714205162017 @default.
• W2071420516 countsByYear W20714205162018 @default.
• W2071420516 countsByYear W20714205162019 @default.
• W2071420516 countsByYear W20714205162021 @default.
• W2071420516 countsByYear W20714205162023 @default.
• W2071420516 crossrefType "journal-article" @default.

• next